3000 Daily Steps Halve Tau Accumulation in Early Alzheimer's Without Affecting Amyloid

Researchers at an unnamed US institution followed mostly white, well-educated participants using pedometers and serial imaging. Activity showed no effect on amyloid but slowed tau spread in areas tied to memory and function, with benefits plateauing between 5000 and 7500 steps. This decouples exercise from the amyloid-targeting drugs that have dominated recent trials.

The result aligns with two UK cohorts: one of 1139 adults over 50 showing 34-50% lower dementia incidence with moderate activity, and a 78430-person accelerometer study linking 3800 steps to a 25% risk drop. Yet those studies also captured better cardiovascular profiles, leaving open whether walking acts directly via irisin and BDNF or indirectly through reduced diabetes and hypertension.

Reverse causation remains plausible; subtle early symptoms such as hearing loss can curtail activity and accelerate decline. A small Nordic-walking trial of 15 mild-Alzheimer's patients preserved or improved cognition over 24 weeks, hinting at dose and intensity mattering.

Next steps require a larger, more diverse RCT with objective activity tracking, tau-PET endpoints, and adjustment for hearing, sleep, and diet to test whether 3000-step prescriptions alter clinical trajectories within five years.